Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35538810/
The beneficial effects of semaglutide on glycemic control and weight reduction provide a promising treatment for diabetes and obesity in Prader-Willi syndrome, even where other glucagons like peptide-1 receptor agonists...
Conclusions: The beneficial effects of semaglutide on glycemic control and weight reduction provide a promising treatment for diabetes and obesity in Prader-Willi syndrome, even where other glucagons like peptide-1 receptor agonists have failed. Further studies are required to confirm the efficacy and safety of semaglutide in patients with...
Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
Source : https://www.sciencedirect.com/science/article/pii/S1319016422000251?via=ihub
To perform a cost of control analysis of glucagon like peptide-1 receptor agonists (GLP1RA) in Saudi Arabia (SA) and determine the economic impact of adopting GLP1RAs. A budget impact model...
Conclusions: Semaglutide 1 mg once weekly was the most economically favorable GLP1RA; associated with the least CCPPPY, and amount of SAR spent to achieve HbA1c of ≤6.50%/
Conclusions: Semaglutide 1 mg once weekly was the most economically favorable GLP1RA; associated with the least CCPPPY, and amount of SAR spent to achieve HbA1c of...
Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35510038/
1 Department of Cadre Ward, The First Affiliated Hospital of Harbin Medical University, Harbin 150081, China. 2 Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin 150081,...
Conclusion: LIRA inhibited the abnormalities in VSMC calcification mediated by the GLP-1R, which was related to PI3K/Akt and ERK1/2 MAPK pathways. Therefore, the prospect and significance of LIRA in the treatment of DM complicated with AS were clarified.
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35503498/
The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for chronic weight management provides a novel effective strategy against obesity. The reliable models that might...
Relevance: We aimed to review the efficacy of GLP-1 RAs approved for weight management in individuals with and without diabetes and discuss some potential mechanisms for consistently observed differences in efficacy between these two populations.
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35501557/
doi: 10.1007/s13679-022-00474-0. Online ahead of print. 1 First Laboratory of Pharmacology, School of Medicine, Campus of Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. [email protected]. 2 Unit of Reproductive Endocrinology, 1st...
Relevance: Obesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of anti-obesity medications on NAFLD, especially focusing on hepatic histology.